Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study

Our aim was to assess the ability of tocilizumab monotherapy to reduce progressive structural joint damage in rheumatoid arthritis patients at high risk of progression. This study was a subanalysis from a prospective 1-year, multicenter, X-ray-reader-blinded, randomized controlled trial of tocilizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Jun, Garnero, Patrick, van der Heijde, Désirée, Miyasaka, Nobuyuki, Yamamoto, Kazuhiko, Kawai, Shinichi, Takeuchi, Tsutomu, Yoshikawa, Hideki, Nishimoto, Norihiro
Formato: Texto
Lenguaje:English
Publicado: Springer Japan 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036807/
https://www.ncbi.nlm.nih.gov/pubmed/20574648
http://dx.doi.org/10.1007/s10165-010-0325-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036807/
https://www.ncbi.nlm.nih.gov/pubmed/20574648
http://dx.doi.org/10.1007/s10165-010-0325-3

Ejemplares similares